{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:26:31Z","timestamp":1790015191320,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ard.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:00:03Z","timestamp":1758859203000},"page":"114-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-5895","authenticated-orcid":false,"given":"Paula","family":"David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Altaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"Abacar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Giryes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle de Mello","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Scarsbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulveer","family":"Mankia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouvik","family":"Dass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benazir","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ari\u00ebns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ard.2025.09.002_bib0001","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ard.2025.09.002_bib0002","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archinte.159.5.445","article-title":"Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study","volume":"159","author":"Heit","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ard.2025.09.002_bib0003","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejim.2019.08.023","article-title":"Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution","volume":"69","author":"Palareti","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/03009742.2021.2001907","article-title":"Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis","volume":"52","author":"Molander","year":"2023","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0006","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/keaa262","article-title":"The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"22","key":"10.1016\/j.ard.2025.09.002_bib0007","first-page":"7005","article-title":"Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis","volume":"25","author":"Hu","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.09.002_bib0009","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ard.2025.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.42846","article-title":"Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.09.002_bib0011","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/jcm11102704","article-title":"Cardiovascular disease risk in rheumatoid arthritis anno 2022","volume":"11","author":"Dijkshoorn","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2025.09.002_bib0012","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ard.2025.09.002_bib0013","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","article-title":"Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis","volume":"16","author":"Semb","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.09.002_bib0014","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.ard.2025.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1 suppl","key":"10.1016\/j.ard.2025.09.002_bib0016","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1378\/chest.107.1_Supplement.3S","article-title":"Pulmonary embolism: epidemiology","volume":"107","author":"Giuntini","year":"1995","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0017","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-98-6-891","article-title":"Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan","volume":"98","author":"Hull","year":"1983","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.ard.2025.09.002_bib0018","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2020-218915","article-title":"Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?","volume":"79","author":"D\u00f6rner","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.09.002_bib0019","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MBC.0000000000001050","article-title":"Clinical characteristics and outcomes of patients with isolated pulmonary embolism","volume":"32","author":"Lee","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.chest.2020.01.055","article-title":"Isolated pulmonary embolism is associated with a high risk of arterial thrombotic disease: results from the VTEval study","volume":"158","author":"Ten Cate","year":"2020","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ard.2025.09.002_bib0022","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1007\/s10067-021-05911-4","article-title":"Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review","volume":"40","author":"Mori","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.ard.2025.09.002_bib0024","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Br\u00fchl","year":"2012","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MOH.0000000000000666","article-title":"Mechanisms of immunothrombosis in COVID-19","volume":"28","author":"Portier","year":"2021","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"10.1016\/j.ard.2025.09.002_bib0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0027","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jth.15179","article-title":"Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia","volume":"19","author":"Nicolai","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S2213-2600(21)00213-7","article-title":"A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19","volume":"9","author":"McGonagle","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.ard.2025.09.002_bib0029","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","article-title":"Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia","volume":"2","author":"McGonagle","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2214\/AJR.23.28996","article-title":"In situ pulmonary arterial thrombosis: literature review and clinical significance of a distinct entity","volume":"221","author":"Baranga","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1016\/j.ard.2025.09.002_bib0031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ard.2025.09.002_bib0032","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ard.2025.09.002_bib0033","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.ard.2025.09.002_bib0034","doi-asserted-by":"crossref","first-page":"ii39","DOI":"10.1093\/rheumatology\/keaa815","article-title":"JAK1 selective inhibitors for the treatment of spondyloarthropathies","volume":"60","author":"White","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2019.09.005","article-title":"Inhibition of JAK\/STAT signaling in rheumatologic disorders: the expanding spectrum","volume":"87","author":"El Jammal","year":"2020","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0036","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.4049\/jimmunol.1200310","article-title":"Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback","volume":"189","author":"Pattison","year":"2012","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.ard.2025.09.002_bib0037","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.4049\/jimmunol.1501541","article-title":"mTOR mediates IL-23 induction of neutrophil IL-17 and IL-22 production","volume":"196","author":"Chen","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2025.09.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/art.43210","article-title":"Paradoxical activation of entheseal myeloid cells by JAK1 and Tyk2 inhibitors via interleukin-10 antagonism","author":"Giryes","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.09.002_bib0039","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jth.14402","article-title":"Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease","volume":"17","author":"Baker","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0040","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41598-021-81268-7","article-title":"Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro","volume":"11","author":"Shi","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ard.2025.09.002_bib0041","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0042","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"12","key":"10.1016\/j.ard.2025.09.002_bib0043","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/jcm8122072","article-title":"Interleukin-1\u03b2 mediates arterial thrombus formation via NET-associated tissue factor","volume":"8","author":"Liberale","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0044","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.15020","article-title":"Interleukin-12 and its procoagulant effect on erythrocytes, platelets and fibrin(ogen): the lesser known side of inflammation","volume":"180","author":"Page","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2141.2001.03061.x","article-title":"Interleukin 6 and haemostasis","volume":"115","author":"Kerr","year":"2001","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0046","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1055\/s-0038-1648512","article-title":"Tumor necrosis factor induces von Willebrand factor release in healthy humans","volume":"67","author":"van der Poll","year":"1992","journal-title":"Thromb Haemost"},{"issue":"suppl(suppl 1)","key":"10.1016\/j.ard.2025.09.002_bib0047","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1538-7836.2009.03368.x","article-title":"The many faces of tissue factor","volume":"7","author":"Mackman","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.ard.2025.09.002_bib0048","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0049","doi-asserted-by":"crossref","first-page":"H652","DOI":"10.1152\/ajpheart.00825.2009","article-title":"Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-alpha and IL-1beta","volume":"298","author":"Khan","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"10.1016\/j.ard.2025.09.002_bib0050","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.RES.0000171805.24799.fa","article-title":"Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines","volume":"96","author":"Szotowski","year":"2005","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0051","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1160\/TH05-07-0509","article-title":"Structure, function and biology of tissue factor pathway inhibitor-2","volume":"94","author":"Chand","year":"2005","journal-title":"Thromb Haemost"},{"issue":"45","key":"10.1016\/j.ard.2025.09.002_bib0052","doi-asserted-by":"crossref","first-page":"31647","DOI":"10.1074\/jbc.M114.569665","article-title":"Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis","volume":"289","author":"Vadivel","year":"2014","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0053","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/mco.2021.2479","article-title":"Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive Ddimer results","volume":"16","author":"Miyake","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0054","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000524804","article-title":"Tissue factor pathway inhibitor 2: a novel biomarker for predicting asymptomatic venous thromboembolism in patients with epithelial ovarian cancer","volume":"87","author":"Yamanaka","year":"2022","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/s-2007-1004415","article-title":"Protein S and the regulation of activated protein C","volume":"10","author":"Walker","year":"1984","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0056","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1538-7836.2008.02980.x","article-title":"Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor","volume":"6","author":"Ndonwi","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ard.2025.09.002_bib0057","doi-asserted-by":"crossref","first-page":"eadk5836","DOI":"10.1126\/sciadv.adk5836","article-title":"TFPI\u03b1 anticoagulant function is highly dependent on protein S in vivo","volume":"10","author":"Petri","year":"2024","journal-title":"Sci Adv"},{"issue":"8","key":"10.1016\/j.ard.2025.09.002_bib0058","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/jth.13383","article-title":"Factor XII: form determines function","volume":"14","author":"de Maat","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ard.2025.09.002_bib0059","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3390\/ijms22052449","article-title":"Thromboembolic adverse drug reactions in Janus Kinase (JAK) inhibitors: does the inhibitor specificity play a role?","volume":"22","author":"Kotyla","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ard.2025.09.002_bib0060","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4049\/jimmunol.1203084","article-title":"The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells","volume":"191","author":"Wang","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.09.002_bib0061","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/exd.14059","article-title":"The Janus kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development","volume":"29","author":"Stalder","year":"2020","journal-title":"Exp Dermatol"},{"issue":"3","key":"10.1016\/j.ard.2025.09.002_bib0062","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2141.2000.01925.x","article-title":"Interleukin 10 regulates cellular responses in monocyte\/endothelial cell co-cultures","volume":"108","author":"Noble","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0063","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1538-7836.2008.02956.x","article-title":"Tissue factor and IL8 production by P-selectin-dependent platelet-monocyte aggregates in whole blood involves phosphorylation of Lyn and is inhibited by IL10","volume":"6","author":"Christersson","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0064","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2141.1996.d01-1893.x","article-title":"Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines","volume":"95","author":"Ernofsson","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib0065","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1365-2141.1998.00808.x","article-title":"IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood","volume":"102","author":"Lindmark","year":"1998","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ard.2025.09.002_bib0066","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/01.RES.0000177893.24574.13","article-title":"Interleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element\/MEK-ERK1\/2 pathway","volume":"97","author":"Kamimura","year":"2005","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.ard.2025.09.002_bib0067","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.ard.2025.09.002_bib0068","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jth.13265","article-title":"The influence of corticosteroids on hemostasis in healthy subjects","volume":"14","author":"Majoor","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ard.2025.09.002_bib0069","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjh.17388","article-title":"Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study","volume":"193","author":"Orsi","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ard.2025.09.002_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004045","article-title":"Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects","volume":"10","author":"David","year":"2024","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.ard.2025.09.002_bib0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.ard.2025.03.014","article-title":"Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies","volume":"84","author":"Alabbasi","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:52:22Z","timestamp":1777377142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725043833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0003496725043833"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.09.002","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}